/

Other

/

Calliditas Therapeutics

Calliditas Therapeutics

Calliditas Therapeutics

Verified Nov 2026

Other

·

Stockholm, Stockholm County

·

Since 2004

Calliditas Therapeutics is a specialty biopharmaceutical company headquartered in Stockholm, Sweden, founded in 2004. The company employs 200-500 people and generates estimated revenue of $100-250 million annually. It develops and commercializes therapies for rare renal and hepatic diseases, with TARPEYO® (budesonide) approved for primary IgA nephropathy and a pipeline including setanaxib for primary biliary cholangitis and Alport syndrome. As of September 2026, the company joined Asahi Kasei Therapeutics.

Calliditas Therapeutics

Verified Nov 2026

AT A GLANCE

Founded

2004

Headquarters

Stockholm, Stockholm County

Employees

200-500

Ownership

Calliditas Therapeutics at a glance

Revenue

$100-250M

Est. band

Employees

200-500

Founded

2004

Headquarters

Stockholm, Stockholm County

Industries

Automotive

Electric Vehicles

Medical

Overview

Calliditas Therapeutics is a specialty biopharmaceutical company headquartered in Stockholm, Sweden, founded in 2004. The company employs 200-500 people and generates estimated revenue of $100-250 million annually. It develops and commercializes therapies for rare renal and hepatic diseases, with TARPEYO® (budesonide) approved for primary IgA nephropathy and a pipeline including setanaxib for primary biliary cholangitis and Alport syndrome. As of September 2026, the company joined Asahi Kasei Therapeutics.

At a glance

Attribute

Detail

Founded

2004

Headquarters

Stockholm, Stockholm County

Employees

200-500

Revenue

$100-250M (estimated)

What Calliditas Therapeutics makes

The company manufactures and supplies pharmaceutical products, with approved commercialized therapies including TARPEYO® and Kinpeygo® alongside clinical-stage candidates advancing through development.

Latest developments

Company details

Calliditas operates as a commercial-stage biopharmaceutical company focused on addressing unmet medical needs in nephrology and hepatology through drug discovery, clinical development, and manufacturing. Calliditas Therapeutics was founded in 2004, has an estimated 200-500 employees, and is headquartered in Stockholm, Stockholm County.

Frequently asked questions

What does Calliditas Therapeutics do?

Calliditas Therapeutics is a specialty biopharmaceutical company headquartered in Stockholm, Sweden, founded in 2004. The company employs 200-500 people and generates estimated revenue of $100-250 million annually. It develops and commercializes therapies for rare renal and hepatic diseases, with TARPEYO® (budesonide) approved for primary IgA nephropathy and a pipeline including setanaxib for primary biliary cholangitis and Alport syndrome. As of September 2026, the company joined Asahi Kasei Therapeutics.

Where is Calliditas Therapeutics headquartered?

Calliditas Therapeutics is headquartered in Stockholm, Stockholm County (26B Wallingatan, Stockholm, Stockholm County, 111 60).

When was Calliditas Therapeutics founded?

Calliditas Therapeutics was founded in 2004.

How big is Calliditas Therapeutics?

Calliditas Therapeutics has an estimated 200-500 employees, with revenue in the $100-250M range (estimated).

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

Stockholm, Stockholm County (HQ)Headquarters · Sweden
Stockholm, Stockholm County (HQ)26B Wallingatan, Stockholm, Stockholm County, 111 60, SwedenHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.